Investigation into ATyr Pharma's Securities Practices and Potential Class Action Lawsuit

ATyr Pharma investors who suffered losses exceeding $50,000 between Jan. 16, 2025, and Sept. 12, 2025, are encouraged to contact Faruqi & Faruqi partner Josh Wilson to discuss their options. The firm is investigating potential claims against ATyr and reminds investors of the Dec. 8, 2025, deadline to seek the role of lead plaintiff in a federal securities class action. The complaint alleges that the company and its executives violated federal securities laws by making false and misleading statements about the efficacy of Efzofitimod. After the results were released, the stock dropped by 83.25%.